Roche: CHMP greenlights Venclyxto
(CercleFinance.com) - Roche announces that the CHMP of the European Medicines Agency has approved Venclyxto, in combination with Gazyvaro, for the treatment of adults suffering from previously untreated chronic lymphocytic leukemia.
This opinion is based on the results of a pivotal phase III study that demonstrated a 65% reduction in the risk of the disease worsening or death with this combination, compared to the current standard of care.
Jointly developed by Roche and the US group AbbVie, Venclyxto is marketed jointly by AbbVie and Genentech (subsidiary of the Swiss health group) in the US, and by AbbVie alone elsewhere.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
This opinion is based on the results of a pivotal phase III study that demonstrated a 65% reduction in the risk of the disease worsening or death with this combination, compared to the current standard of care.
Jointly developed by Roche and the US group AbbVie, Venclyxto is marketed jointly by AbbVie and Genentech (subsidiary of the Swiss health group) in the US, and by AbbVie alone elsewhere.
Copyright (c) 2020 CercleFinance.com. All rights reserved.